Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation

January 8, 2024

https://www.globenewswire.com/news-release/2024/01/08/2805383/0/en/Landos-Biopharma-to-Present-New-Data-on-Immunometabolism-at-the-19th-Annual-Congress-of-the-European-Crohn-s-and-Colitis-Organisation.html

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ:LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that six abstracts were accepted for poster presentation at the 19th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO). The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69. The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden.

Read more at globenewswire.com

Related news for (LABP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.